ClinicalTrials.gg
CompletedNCT01271712GRIDUpdated Jan 29, 2021Results posted

Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)

A Phase 3 interventional study of Regorafenib (Stivarga, BAY73-4506) and Placebo in Gastrointestinal Stromal Tumors, sponsored by Bayer. Completed at 57 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-29.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
199
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing regorafenib in Gastrointestinal Stromal Tumors — 1 open to participants now, 3 under way, none of them phase 3. regorafenib · Gastrointestinal Stromal Tumors.

Enrollment
Largest of 10
199 · median 28
Started
2011
the only one that year
Phase 3
Only one
of the 10
Registered
2nd of 10
by date
Lead sponsor
1 of 10
Bayer

Among the 10 studies testing regorafenib in Gastrointestinal Stromal Tumors, this one has the largest enrollment, is the only one that started in 2011, is the only one in phase 3, and was the 2nd registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

1 of the 10 studies testing regorafenib in Gastrointestinal Stromal Tumors is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About regorafenib

regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing regorafenib in Gastrointestinal Stromal Tumors, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib.

The study is composed of 3 periods: A Screening Period, a Treatment Period, and a Survival Follow up Period.

Subjects randomized to be treated with regorafenib will receive 160 mg po od for 3 weeks of every 4 week (28 day) cycle (ie, 3 weeks on/1 week off). In addition subjects will receive best supportive care which excludes any disease specific anti cancer therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgery.

Tumor assessment will be every 4 weeks for the first 3 months, every 6 weeks for the next 3 months (through month 6), and every 8 weeks until the end of treatment, or more frequently if clinically indicated. Tumor assessments include CT or MRI and will be performed until tumor progression is seen in a central radiology review.

Subjects receiving placebo who experience disease progression may be offered active treatment.

Subjects who experience progression during regorafenib treatment may continue open label treatment.

All subjects will enter the Survival Follow-up Period upon discontinuation of randomized study treatment.

03

Conditions studied

  • Gastrointestinal Stromal Tumors

Keywords

  • Gastrointestinal stromal cancer
  • GIST
  • multikinase inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects 18 years of age.
  • Subjects with confirmed and/or unresectable GIST.
  • At least imatinib and sunitinib as prior treatment regimens, with objective disease progression or intolerance to imatinib, as well as disease progression while on sunitinib therapy. Additionally, disease progression or intolerance to other systemic therapies, as well as new agents, is allowed, except prior treatment with any other vascular endothelial growth factor receptor (VEGFR) inhibitor.
  • Subjects must have at least one according to (RECIST), version 1.1. A lesion in a previously irradiated area is eligible to be considered as measurable disease as long as there is objective evidence of progression of the lesion prior to study enrollment.

(ECOG) Performance Status of 0 or 1.

  • Adequate bone marrow, liver, and renal function as assessed by laboratory parameters.

Recovery to v4.0 Grade 0 or 1 level or recovery to baseline preceding the prior treatment from any previous drug/procedure-related toxicity (except alopecia and anemia).

Exclusion criteria

Exclusion Criteria:

  • Major surgical procedure, open , or significant traumatic injury within 28 days before start of study medication.
  • Congestive heart failure (NYHA) class 2.
  • Unstable angina (angina symptoms at rest, new-onset angina, ie, within the last 3 months) or myocardial infarction (MI) within the past 6 months before start of study medication.
  • Uncontrolled hypertension (systolic blood pressure 140 mmHg or diastolic pressure 90 mmHg despite optimal medical management).

Arterial thrombotic or embolic events such as cerebrovascular accident (including ), or pulmonary embolism within the 6 months before start of study drug or venous thrombotic events such as deep vein thrombosis within the 3 months before start of study drug.

  • Ongoing infection grade 2 National Cancer Institute- (NCI CTCAE) version 4.0.

Symptomatic brain or meningeal tumors.

  • Subjects with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event NCI-CTCAE version 4.0 grade 3 or higher within 4 weeks prior to the start of study drug.

Non-healing wound, ulcer, or bone fracture.

  • Persistent proteinuria of NCI-CTCAE version 4.0 grade 3 or higher (3.5 g/24 hrs, measured by urine protein:creatinine ratio on a random urine sample).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
199 participants (actual)

Study arms

  • Experimental
    Regorafenib (Stivarga, BAY73-4506)

    Participants received Regorafenib (Stivarga) 160 mg (4 x 40 mg tablets) per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks

    Drug: Regorafenib (Stivarga, BAY73-4506) · Drug: Best supportive care

  • Placebo comparator
    Placebo

    Participants received matching Placebo tablets per os once daily, 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks

    Drug: Placebo · Drug: Best supportive care

Interventions

  • 160 mg po once daily (od), 3 weeks on/1 week off. Route of administration: oral

  • DrugPlacebo

    once daily (od), 3 weeks on/1 week off. Route of administration: oral

  • DrugBest supportive care

    Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival

    Progression-free Survival (PFS) was defined as the time from date of randomization to radiological disease progression or death due to any cause, whichever occurs first. PFS was based on central radiological assessment using modified RECIST (Response Evaluation Criteria in Solid Tumors) v.1.1. Progression is defined as at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study; or unequivocal progression of existing non-target lesions; or appearance of new lesions. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation. Results are based on central evaluation.

    Time frame: From randomization of the first subject until approximately 144 progression-free survival events had occurred (study duration approximately one year)

Secondary outcomes

  1. Overall Survival

    Overall Survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their date of last contact. Median OS was not observed at the time of PFS analysis and first analysis of OS, therefore only the proportion of death events was reported in the results posting system. This approach was maintained for the subsequent updates in the results posting system.

    Time frame: From randomization of the first subject until date of database cutoff (08 Jun 2015)

  2. Time to Progression (TTP)

    Time to progression (TTP) was defined as the time from date of randomization to disease progression (based on central radiological assessment using modified RECIST \[Response Evaluation Criteria in Solid Tumors\] v.1.1). Progression is defined as at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study; or unequivocal progression of existing non-target lesions; or appearance of new lesions. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation. Results are based on central evaluation.

    Time frame: From randomization of the first subject until until date of database cutoff (26 Jan 2012); study duration approximately 1 year

  3. Tumor Response

    Tumor Response of a subject was defined as the best tumor response (Complete Response \[CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).\], Partial Response \[PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.\], Stable Disease \[SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.\], or Progressive Disease \[PD: at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study or unequivocal progression of existing non-target lesions, or appearance of new lesions.\]) observed during the trial period and assessed according to RECIST v1.1 criteria. Results are based on central evaluation.

    Time frame: From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year

  4. Objective Response Rate

    Objective response rate was defined as the percentage of subjects whose best response was Complete Response (CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Results are based on central evaluation.

    Time frame: From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year.

  5. Disease Control Rate (DCR)

    Disease Control Rate (DCR) was defined as the percentage of subjects whose best response was Complete Response (CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).), Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.), or Stable Disease (SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.) according to RECIST v1.1 criteria. SD had to be maintained for at least 12 weeks from the first demonstration of that rating. Results are based on central evaluation.

    Time frame: From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year

  6. Duration of Response (DOR)

    Duration of Response was defined as the time from date of first response (Complete Response \[CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).\] or Partial Response \[PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.\]) to the date when Progressive Disease (PD: at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study or unequivocal progression of existing non-target lesions, or appearance of new lesions.) is first documented, or to the date of death, whichever occurs first, according to RECIST v1.1. Subjects still having CR or PR and have not died at the time of analysis were censored at their last date of tumor evaluation. Duration of response defined for responders only, i.e CR or PR. Results are based on central evaluation.

    Time frame: From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year

07

Results

Posted Oct 25, 2013
Limitations and caveats
Overall survival results are confounded by the fact that 85% of the participants initially randomized to placebo switched to open-label regorafenib.

Participant flow

A total of 240 participants with metastatic and/or unresectable GIST whose disease had progressed despite prior treatments with at least imatinib and sunitinib were screened; 199 were randomized. Patients must have shown objective disease progression or intolerance to imatinib, as well as disease progression while on sunitinib treatment.

Double Blind Treatment
Participant flow — Double Blind Treatment
MilestoneRegorafenib (Stivarga, BAY73-4506)Placebo First, Then Option of Open Label Regorafenib Treatment
Started13366
Participants received treatment13266
Completed9158
Not completed428
Withdrew: Death20
Withdrew: Lack of efficacy10
Withdrew: Adverse event94
Withdrew: Progressive disease233
Withdrew: Withdrawal by subject41
Withdrew: Non compliance with study drug20
Withdrew: Receive no study drug10
Open Label Treatment
Participant flow — Open Label Treatment
MilestoneRegorafenib (Stivarga, BAY73-4506)Placebo First, Then Option of Open Label Regorafenib Treatment
Started9158
Completed00
Not completed9158
Withdrew: Death65
Withdrew: Withdrawal by subject611
Withdrew: Physician decision20
Withdrew: Adverse event148
Withdrew: Progressive disease5932
Withdrew: Transferred to rollover study10
Withdrew: Non-compliance with study drug10
Withdrew: Protocol violation01
Withdrew: Switching to other therapy21
Safety Follow-up
Participant flow — Safety Follow-up
MilestoneRegorafenib (Stivarga, BAY73-4506)Placebo First, Then Option of Open Label Regorafenib Treatment
Started11852
Completed9737
Not completed2115
Withdrew: Death117
Withdrew: Withdrawal by subject42
Withdrew: Protocol violation11
Withdrew: Not analyzed after cutoff 08jun201534
Withdrew: No follow-up11
Withdrew: Progressive disease10
Survival Follow-up
Participant flow — Survival Follow-up
MilestoneRegorafenib (Stivarga, BAY73-4506)Placebo First, Then Option of Open Label Regorafenib Treatment
Started10039
Completed8533
Not completed156
Withdrew: Not analyzed after cutoff 08jun2015156

Outcome measures

PrimaryProgression-free Survival

Progression-free Survival (PFS) was defined as the time from date of randomization to radiological disease progression or death due to any cause, whichever occurs first. PFS was based on central radiological assessment using modified RECIST (Response Evaluation Criteria in Solid Tumors) v.1.1. Progression is defined as at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study; or unequivocal progression of existing non-target lesions; or appearance of new lesions. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation. Results are based on central evaluation.

Time frame:
From randomization of the first subject until approximately 144 progression-free survival events had occurred (study duration approximately one year)
Reported as:
Median · Days
Progression-free Survival
DaysRegorafenib (Stivarga, BAY73-4506)Placebo
Progression-free Survival147 (122 to 173)28 (28 to 32)
Statistical analysis
  • Regorafenib (Stivarga, BAY73-4506) vs Placebo · Log Rank · p = <0.000001stratified
  • Regorafenib (Stivarga, BAY73-4506) vs Placebo · Regression, Cox · Hazard ratio (hr): 0.268 · 95% CI 0.185 to 0.388regorafenib over placebo
SecondaryOverall Survival

Overall Survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their date of last contact. Median OS was not observed at the time of PFS analysis and first analysis of OS, therefore only the proportion of death events was reported in the results posting system. This approach was maintained for the subsequent updates in the results posting system.

Time frame:
From randomization of the first subject until date of database cutoff (08 Jun 2015)
Reported as:
Number · Percentage of patients with death
Overall Survival
Percentage of patients with deathRegorafenib (Stivarga, BAY73-4506)Placebo
Overall Survival82.080.3
Statistical analysis
  • Regorafenib (Stivarga, BAY73-4506) vs Placebo · Log Rank · p = 0.285777stratified
  • Regorafenib (Stivarga, BAY73-4506) vs Placebo · Regression, Cox · Hazard ratio (hr): 0.909 · 95% CI 0.653 to 1.265regorafenib over control. 58 (87.9%) patients in placebo group and 91 (68.4%) patients in regorafenib had started open-label treatment with regorafenib before time of final database cutoff 08 Jun 2015.
SecondaryTime to Progression (TTP)

Time to progression (TTP) was defined as the time from date of randomization to disease progression (based on central radiological assessment using modified RECIST \[Response Evaluation Criteria in Solid Tumors\] v.1.1). Progression is defined as at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study; or unequivocal progression of existing non-target lesions; or appearance of new lesions. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation. Results are based on central evaluation.

Time frame:
From randomization of the first subject until until date of database cutoff (26 Jan 2012); study duration approximately 1 year
Reported as:
Median · Days
Time to Progression (TTP)
DaysRegorafenib (Stivarga, BAY73-4506)Placebo
Time to Progression (TTP)165 (125 to 174)28 (28 to 34)
Statistical analysis
  • Regorafenib (Stivarga, BAY73-4506) vs Placebo · Log Rank · p = <0.000001stratified
  • Regorafenib (Stivarga, BAY73-4506) vs Placebo · Regression, Cox · Hazard ratio (hr): 0.248 · 95% CI 0.170 to 0.364stratified
SecondaryTumor Response

Tumor Response of a subject was defined as the best tumor response (Complete Response \[CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).\], Partial Response \[PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.\], Stable Disease \[SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.\], or Progressive Disease \[PD: at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study or unequivocal progression of existing non-target lesions, or appearance of new lesions.\]) observed during the trial period and assessed according to RECIST v1.1 criteria. Results are based on central evaluation.

Time frame:
From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year
Reported as:
Number · Percentage of Participants
Tumor Response
Percentage of ParticipantsRegorafenib (Stivarga, BAY73-4506)Placebo
Complete Response (CR)0 (0 to 0)0 (0 to 0)
Partial Response (PR)4.5 (1.7 to 9.6)1.5 (0 to 8.2)
Stable Disease (SD)71.4 (63.0 to 78.9)33.3 (22.2 to 46.0)
Progressive Disease (PD)21.1 (14.5 to 29.0)63.6 (50.9 to 75.1)
Not Assessable3.0 (0.8 to 7.5)1.5 (0 to 8.2)
SecondaryObjective Response Rate

Objective response rate was defined as the percentage of subjects whose best response was Complete Response (CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Results are based on central evaluation.

Time frame:
From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year.
Reported as:
Number · Percentage of Participants
Objective Response Rate
Percentage of ParticipantsRegorafenib (Stivarga, BAY73-4506)Placebo
Objective Response Rate4.5 (1.7 to 9.6)1.5 (0.0 to 8.2)
SecondaryDisease Control Rate (DCR)

Disease Control Rate (DCR) was defined as the percentage of subjects whose best response was Complete Response (CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).), Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.), or Stable Disease (SD: steady state of disease. Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.) according to RECIST v1.1 criteria. SD had to be maintained for at least 12 weeks from the first demonstration of that rating. Results are based on central evaluation.

Time frame:
From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR)
Percentage of ParticipantsRegorafenib (Stivarga, BAY73-4506)Placebo
Disease Control Rate (DCR)52.6 (43.8 to 61.3)9.1 (3.4 to 18.7)
SecondaryDuration of Response (DOR)

Duration of Response was defined as the time from date of first response (Complete Response \[CR: disappearance of all clinical and radiological evidence of tumor (both target and non-target).\] or Partial Response \[PR: at least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing non-target lesions, and no appearance of new lesions.\]) to the date when Progressive Disease (PD: at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study or unequivocal progression of existing non-target lesions, or appearance of new lesions.) is first documented, or to the date of death, whichever occurs first, according to RECIST v1.1. Subjects still having CR or PR and have not died at the time of analysis were censored at their last date of tumor evaluation. Duration of response defined for responders only, i.e CR or PR. Results are based on central evaluation.

Time frame:
From randomization of the first subject until date of database cutoff (26 Jan 2012); study duration approximately 1 year
Reported as:
Median · Days
Duration of Response (DOR)
DaysRegorafenib (Stivarga, BAY73-4506)Placebo
Duration of Response (DOR)99 (42 to NA)30 (NA to NA)

Adverse events

Collected over From first administration of treatment till 30 days after last dose of treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regorafenib (Double Blind Only)40/41 (97.6%)23/41 (56.1%)40/41 (97.6%)
Placebo (Double Blind Only)7/8 (87.5%)8/8 (100%)7/8 (87.5%)
Placebo, Open Label Only (Switch to Regorafenib)47/58 (81%)31/58 (53.4%)58/58 (100%)
Treated With Regorafenib at Any Time155/190 (81.6%)103/190 (54.2%)189/190 (99.5%)
Treated With Regorafenib for > 1 Year48/75 (64%)39/75 (52%)75/75 (100%)
Most frequent serious events
Showing 10 of 105
Most frequent serious events
EventRegorafenib (Double Blind Only)Placebo (Double Blind Only)Placebo, Open Label Only (Switch to Regorafenib)Treated With Regorafenib at Any TimeTreated With Regorafenib for > 1 Year
Death NOSGeneral disorders1/412/81/583/1902/75
NauseaGastrointestinal disorders0/411/81/582/1901/75
FatigueGeneral disorders2/411/82/585/1902/75
Non-cardiac chest painGeneral disorders0/411/80/580/1900/75
General disorders and administration site conditions - OtherGeneral disorders1/411/82/585/1903/75
Hepatobiliary disorders - OtherHepatobiliary disorders0/411/81/582/1901/75
DehydrationMetabolism and nutrition disorders0/411/80/583/1903/75
HyperglycemiaMetabolism and nutrition disorders0/411/80/580/1900/75
ManiaPsychiatric disorders0/411/80/580/1900/75
Abdominal painGastrointestinal disorders5/410/82/589/1901/75
Most frequent other events
Showing 10 of 105
Most frequent other events
EventRegorafenib (Double Blind Only)Placebo (Double Blind Only)Placebo, Open Label Only (Switch to Regorafenib)Treated With Regorafenib at Any TimeTreated With Regorafenib for > 1 Year
HypertensionVascular disorders18/413/837/58124/19062/75
Palmar-plantar erythrodysesthesia syndromeSkin and subcutaneous tissue disorders17/411/839/58126/19058/75
DiarrheaGastrointestinal disorders15/411/824/5896/19053/75
ConstipationGastrointestinal disorders10/415/816/5863/19028/75
FatigueGeneral disorders18/413/832/58104/19046/75
Mucositis oralGastrointestinal disorders14/412/821/5881/19038/75
AlopeciaSkin and subcutaneous tissue disorders7/410/821/5862/19033/75
NauseaGastrointestinal disorders9/413/818/5861/19032/75
AnorexiaMetabolism and nutrition disorders15/413/820/5877/19032/75
PainGeneral disorders5/411/819/5855/19029/75

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Regorafenib (Stivarga, BAY73-4506)PlaceboTotal
Mean58.2 ± 12.558.1 ± 13.958.2 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)Regorafenib (Stivarga, BAY73-4506)PlaceboTotal
Female482472
Male8542127
ECOG Performance Status (PS)]
ECOG Performance Status (PS)](Participants)Regorafenib (Stivarga, BAY73-4506)PlaceboTotal
PS 07337110
PS 1602989
PS 2000
Missing000
Prior anti-cancer drug group
Prior anti-cancer drug group(Participants)Regorafenib (Stivarga, BAY73-4506)PlaceboTotal
3rd line7439113
4th line and beyond592786
08

Study locations

57 sites
  • Scottsdale, Arizona 85258, United States
  • Evanston, Illinois 60201, United States
  • Skokie, Illinois 60076, United States
  • Boston, Massachusetts 02115, United States
  • Minneapolis, Minnesota 55455, United States
  • New York, New York 10065, United States
  • Portland, Oregon 97239-2964, United States
  • Philadelphia, Pennsylvania 19111-2497, United States
  • Seattle, Washington 98109, United States
  • Graz, Steiermark 8036, Austria
  • Innsbruck, 6020, Austria
  • Wien, 1090, Austria
  • Leuven, 3000, Belgium
  • Edmonton, Alberta T6G 1Z2, Canada
  • London, Ontario N6A 4L6, Canada
  • Toronto, Ontario M5G 1X5, Canada
  • Guangzhou, Guangdong 510060, China
  • Nanjing, Jiangsu 210002, China
  • Beijing, 100071, China
  • Shanghai, 200030, China
  • Helsinki, 00290, Finland
  • Bordeaux Cedex, 33076, France
  • Lille Cedex, 59020, France
  • Lyon Cedex 08, 69373, France
  • Villejuif, 94805, France
  • Mannheim, Baden-Württemberg 68167, Germany
  • Tübingen, Baden-Württemberg 72076, Germany
  • Bad Saarow, Brandenburg 15526, Germany
  • Hannover, Niedersachsen 30625, Germany
  • Düsseldorf, Nordrhein-Westfalen 40479, Germany
  • Essen, Nordrhein-Westfalen 45122, Germany
  • Köln, Nordrhein-Westfalen 50924, Germany
  • Tel Aviv, 64239, Israel
  • Bologna, Emilia-Romagna 40138, Italy
  • Milano, Lombardia 20133, Italy
  • Torino, Piemonte 10060, Italy
  • Palermo, Sicilia 90127, Italy
  • Nagoya, Aichi 466-8650, Japan
  • Kashiwa, Chiba 277-8577, Japan
  • Sapporo, Hokkaido 060-8648, Japan
  • Chuo-ku, Tokyo 104-0045, Japan
  • Niigata, 951-8520, Japan
  • Osaka, 543-0035, Japan
  • Goyang-si, Gyeonggido 410-769, Korea, Republic of
  • Busan, 49201, Korea, Republic of
  • Seoul, 03080, Korea, Republic of
  • Seoul, 06351, Korea, Republic of
  • Seoul, 138-736, Korea, Republic of
  • Leiden, 2333 ZA, Netherlands
  • Nijmegen, 6525 GA, Netherlands
  • Warszawa, 02-781, Poland
  • Singapore, 169610, Singapore
  • L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Barcelona, 08035, Spain
  • Leicester, Leicestershire LE1 5WW, United Kingdom
  • London, SW3 6JJ, United Kingdom
  • Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schoffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22. PubMed 23177515 ↗
  • Poole CD, Connolly MP, Chang J, Currie CJ. Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo. Gastric Cancer. 2015 Jul;18(3):627-34. doi: 10.1007/s10120-014-0391-x. Epub 2014 Jun 24. PubMed 24957256 ↗
  • Komatsu Y, Doi T, Sawaki A, Kanda T, Yamada Y, Kuss I, Demetri GD, Nishida T. Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. Int J Clin Oncol. 2015 Oct;20(5):905-12. doi: 10.1007/s10147-015-0790-y. Epub 2015 Feb 6. PubMed 25655899 ↗
  • Mross K, Frost A, Steinbild S, Hedbom S, Buchert M, Fasol U, Unger C, Kratzschmar J, Heinig R, Boix O, Christensen O. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012 May 1;18(9):2658-67. doi: 10.1158/1078-0432.CCR-11-1900. Epub 2012 Mar 15. PubMed 22421192 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2011 to primary completion in Jan 2012, 12 months.

Results were first posted in Oct 2013, 1 year 8 months after primary completion. A results delay was requested in Jan 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2010
First posted
Jan 7, 2011
StartActual
Jan 4, 2011
Primary completionActual
Jan 26, 2012
CompletionActual
Apr 15, 2019
Results delay requested
Jan 30, 2013
Results first posted
Oct 25, 2013
Last update
Jan 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01271712
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 7, 2011
Start date
Jan 4, 2011
Primary completion
Jan 26, 2012
Completion
Apr 15, 2019
Results posted
Oct 25, 2013
Last update
Jan 29, 2021

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regorafenib

Start the discussion